These results suggest that CD109-induced STAT3 phosphorylation leads to NOTCH1 activation, which leads to the reciprocal inhibition of STAT3, and that CD109-induced drug resistance in ovarian cancer cells is regulated via the STAT3-NOTCH1 signaling axis (Figure 6D). The gene discussed is STAT3; the disease is ovarian carcinoma.